We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Travala.com is a leading blockchain travel company with over 2 million listings covering 90,124 destinations in 230 countries and territories across the globe. Offering travellers payment options through 20+ cryptocurrencies in addition to credit/debit cards, Travala aims to be 15% cheaper than the rest of the market. Moreover, the company is in strategic partnership with Booking.com. Travala's user base has also increased to over 20K registered users with over 90% organic growth to date. With the proceeds, Travala plans to release its native iOS and Android apps, increase customer support operations worldwide, boost marketing activities, secure more high-profile partnerships from both the blockchain and travel space.

Pitch Rated

65%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £367,580
Lovetovisit is a platform that seamlessly combines inspiration and convenient booking for a wide range of family-friendly activities, ensuring that they enjoy memorable experiences at the best prices. They utilize data-driven content and their proprietary API technology to transform how people discover and purchase tickets for various attractions, events, and experiences. Their mobile-first API technology ensures quick ticket purchases, enhancing convenience. Lovetovisit provides an extensive selection of unique attractions and events, fostering customer loyalty and network effects. Leveraging two decades of supplier relationships, they offer exceptional deals and discounts. The platform is now expanding internationally and enhancing the user experience with video and AI-driven content, continuing to be a mobile-first destination for families seeking affordable and exciting attractions, events, and experiences.
days to go: Expired investment: £328,705
Polysolar specialises in manufacturing photovoltaic windows capable of generating electricity, which can be used in buildings to generate clean renewable energy whilst also meeting planning regulations. Its technology is already in-use by major organisations such as Network Rail and Sainsbury's.

Pitch Rated

69%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,311,180
WELD is a fitness company on a mission to make on-demand health, fitness and wellbeing available to all ages & abilities. The company allows users and instructors to set the time and place for the training session, rent out their home or commercial spaces for activities, or interact 1-2-1 online. This approach, the company believes, helps personal trainers, hit by the Covid-19 lockdown, find clients. WELD also allows trainers to set their prices and keep 90% of their fees, and lets customers enjoy a 2% commission on referrals for every future session taken in perpetuity. WELD aims to tap into the $94 billion global fitness and wellness market that grew 8.7% from 2018/19. The company's primary target audience is Generation Z that, the company believes, embraced wellness. WELD will use the investment to improve its platform, boost marketing and plug the fitness & wellness gap. 

Pitch Rated

56%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £199,227
Exchange Train (ET) is an online comparison website where property solicitors have 24 hours to bid for the home-movers custom in real-time. ET argues that there are over 19,000 property solicitors in the UK each providing a different quality of service, price, and turnaround time. ET aims to overhaul this process. Its portal locates the top solicitors for the customer’s specific transaction, based not only on price but what's most important to the customer. ET has had over 10,000 visitors, generated over 650 quotes, and signed up 22 solicitors on its portal, to date. The company has also featured in TodaysConveyancer, The Property Industry Eye, and The Negotiator Magazine. It will use 30% of the investment towards accelerating website development, 36% towards boosting Public Relations (PR), 18% towards enhancing Google Ads and social media, and 16% towards growing business operations.

Pitch Rated

41%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £123,900
planarTECH is an engineering company founded in 2014 as a provider of process equipment for the growth and characterisation of graphene and other emerging 2D materials. Its core product line is the planarGROW Chemical Vapor (CVD) system. The company has the ability to deliver scalable production systems that allow lower-cost production of graphene in comparison to other options currently available in the market. Moreover, from 2014 to 2019, the company’s cumulative revenues exceeded £5 million. The company's products have been installed and used by faculties and students at prestigious universities like Stanford University (USA), IIT- Bombay (India), Deakin University (Australia), and many others. From the investment, the company will utilise 45% as working capital, 30% in Capital Expenditures (CAPEX), 15% in R&D and 10% in hiring additional staff.

Pitch Rated

47%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £425,061
Bioepic is an app which enables users to easily and non-invasively measure their health status in just 30 seconds using just a smartphone. The app calculates pulse wave velocity, body temperature, blood pressure, heart rate variability chaos, vascular stiffness and the effectiveness of inhalers. 
days to go: Expired investment: £12,500
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph